Chronic Hepatitis C

Google_______________
Index of All Hepatitis C Articles by Topic ( A to Z)

A
2-log Drop
Acute (Primary) HCV Infection
African Americans
Age
Alcohol / Smoking / Diabetes
ALT
Alternative Medications
Anemia
Assistant Programs

HCV Main Sections

HCV FDA-approved Drugs
 HCV Experimental Treatments
HCV / HCV-Drug Related Adverse Events
HCV Liver Issues
HCV Tests
HCV Transplantation
Treatment Guidelines
HCV Conference Coverage

 

 FDA-approved Monotherapy
Intron A (interferon alfa-2b)
Roferon (interferon alfa-2a)
Infergen (consensus interferon)
Pegasys (peginterferon alfa-2a)
PEG-Intron (peginterferon alfa-2b)

 

 FDA-approved Combination Therapy
Pegasys + Copegus
- (peginterferon alfa-2a + ribavirin)
PEG-Intron + Rebetol
- (peginterferon alfa-2b + ribavirin)
Intron A + Rebetol
- (standard interferon alfa-2b + ribavirin)
Roferon A + Ribavirin
-(interferon alfa-2a + ribavirin)

Rebetol (ribavirin) / Copegus (ribavirin)  
Rebetol / Copegus

 

 HCV Liver Issues

Liver Biopsy
Cirrhosis
End Stage Liver Disease
Fibrosis
Hepatocellular Carcinoma
Liver Histology
Liver Stiffness Measurement (LSM)
Liver Transplantation
Non-Alcoholic Fatty Liver Disease (NAFLD)
Steatosis

 

 HCV / HCV-Drug Related Adverse Events

Anemia
Arrhythmias
Cirrhosis
CNS disorders
Cryoglobulinemia
Diabetes
Extrahepatic condition
Fatigue
Fibrosis
Hemotological Disorders
Kidney Disorders
Neutropenia
Psychiatric
Retinopathy
Steatosis
Bowel Disease

 HCV Tests

HCV Tests - Main Page  
ALT / AST  
bDNA (Quantitative)
Caspase activity
FibroTest/ ActiTest
Genotype
HCV antibody
HCV core antigen
HCV RNA (Qualitative)
HCV Qualitative PCR
  (Cobas Amplicor)
Liver Biopsy
Liver Stiffness Measur.
NAT Plasma
RT-PCR (Quantitative)
TMA assays (Qualitative)

 HCV Transplantation

Liver Transplantation
Kidney Transplantation
HCV Recurrence After Transplantation

 Recent HCV Conference Coverage

HIV and Hepatitis.com
Coverage of
 Digestive Disease Week 2006
May 20 - 25, 2006, LA, CA

DDW 2006Main Page

National Institutes of Health Consensus
  Development Conference Statement
  Management of Hepatitis C: 2002   
  June 10-12, 2002, Bethesda, MD

 

 

 

 

B
Bone Density
C
Caucasian
Children
Chronic HCV Infection
Clinical Trials
Cirrhosis
CNS disorders
Cognitive Behavioral Therapy
Combination Treatment
Cost
Cryoglobulinemia / Cryoglobulin
D
Disease Progression
Developing Countries
Depression
Diabetes Mellitus
Dose Reductions for Interferon / Ribavirin
Drug Abuse
Drug Pricing
Drug Related Adverse Events
E
Early Treatment Cessation
Early Virologic Response
End Stage Liver Disease
Epidemiology / African Americans
Epoetin Alpha
Early Viral Response (EVR)
Eradication
Extrahepatic Events
Experimental Treatment
F
Fatigue
Fibrosis
G
Gender
Genotype 1 and 4
Genotype 2 and 3
Genotype 5 and 6
GGT Levels
Glucose Intolerance
Growth Factors
Guidelines
I
 Immunosuppression
Inflammatory Bowel Disease
Injection Drug Use
Infergen (consensus interferon)
Insulin Resistance
Interferon
Intron A (interferon alfa-2b)
Intron A + Rebetol -(standard interferon alfa-2b + ribavirin)
J
K
Kidney Disorders
Kidney Transplant
L
Latinos
Liver Biopsy
Liver Enzymes
Liver Issues
Living Donors
Liver Stiffness Measurement (LSM)
M
 Methadone
Mortality and Morbidity
Monotherapy Treatment
Mother to Child Transmission of HCV
N
Natural History
Neutropenia
Non-Alcoholic Fatty Liver
  Disease (NAFLD)
Non-Hepatic Cancers
Non-Hodgkins Lymphoma
Non-organ Specific Autoantibodies
Nonresponders / Relapsers
O
Obesity
P
 Patient Asistant Programs
Pegasys (peginterferon alfa-2a)
Pegasys + Copegus (peginterferon alfa-2a + ribavirin)
PEG-Intron (peginterferon alfa-2b)
PEG-Intron + Rebetol (peginterferon alfa-2b + ribavirin)
Pegylated Inferferon
Pharmacokinetics
Platelets
Pregnancy
PIIINP/MMP-1, prothrombin time (PT)
Q
Quality of Life
R
Race / Ethnicity
Rapid Virologic Response (RVR)
Recurrent HCV
Re-Treatment
Retinopathy
Ribavirin
Ribavirin Dosing
Risk Factors
Roferon (interferon alfa-2a)
Roferon A + Ribavirin -(interferon alfa-2a + ribavirin)
S
Seroconversion
Sex (gender)
Sexual Transmission
Side Effects
Steatosis
Steroids
Superinfected
Survival
Sustained Viral Response
T
Tests
Toxicities and Side Events
Transmission
Transplantation
U
Undetectable HCV RNA
V
Vaccines
Viral Eradication
Viral Kinetics
Viral Load
W
 Weight-based Dosing
WIN-R Trial
Women and Children
Z